Exhibit 99.1 PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors • Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women's Cancer • Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM ! 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-3218129 (State or other jurisdic ...

Financial Performance - PMV Pharmaceuticals reported a net loss of $68.96 million for the year ended December 31, 2023, compared to a net loss of $73.32 million for the previous year, representing a decrease of approximately 6%[11] - Total operating expenses for the year were $80.13 million, compared to $77.04 million in 2022, marking an increase of approximately 4%[11] - Research and development expenses increased to $55.89 million in 2023 from $51.99 million in 2022, reflecting a rise of about 7% due to increased headcount and clinical expenses[11] - The company had cash, cash equivalents, and marketable securities totaling $228.6 million as of December 31, 2023, down from $243.5 million at the end of 2022[11] Clinical Development - The overall response rate in the Phase 1 PYNNACLE trial for rezatapopt was confirmed at 38%, with a median duration of response of seven months in the intended Phase 2 population[5] - The registrational, tumor-agnostic Phase 2 clinical trial of rezatapopt is on track to initiate in Q1 2024[5] - The company concluded a successful End-of-Phase 1 meeting with the FDA, aligning on the recommended Phase 2 dose and key elements of the Phase 2 registrational portion of the PYNNACLE study[11] - PMV Pharmaceuticals initiated enrollment in the combination arm of the PYNNACLE study with rezatapopt and KEYTRUDA®[11] Strategic Initiatives - PMV Pharmaceuticals expects cost savings from a workforce reduction initiated in January 2024 to extend its cash runway to the end of 2026[5] - The company appointed Charles Baum, M.D., Ph.D., as senior clinical advisor, enhancing its clinical development team[6]

Financial Performance - The net loss for the three months ended September 30, 2023, was $16.6 million, a decrease of $1.6 million compared to a net loss of $18.2 million for the same period in 2022[101]. - The company incurred a net loss of $53.2 million for the nine months ended September 30, 2023, compared to a net loss of $54.0 million for the same period in 2022, reflecting a decrease of $0.8 million[106]. - The accumulated deficit reached $294.2 million as of September 30, 2023, with cash operating expenditures of $43.6 million for the nine months ended September 30, 2023, compared to $48.4 million in 2022[117]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2023, were $13.6 million, a slight decrease of $0.1 million from $13.7 million in the same period in 2022[102]. - Research and development expenses for the nine months ended September 30, 2023, totaled $42.5 million, an increase of $5.5 million from $37.0 million in the same period in 2022[107]. - The company expects significant increases in operating expenses as it advances product candidates through clinical development and seeks regulatory approval[90]. Cash and Financial Assets - As of September 30, 2023, total financial assets were $238.1 million, a decrease of $5.4 million from $243.5 million as of December 31, 2022[111]. - The company expects its cash, cash equivalents, and marketable securities as of September 30, 2023, to be sufficient to fund operations at least through 2025[117]. - As of September 30, 2023, the company had cash, cash equivalents, and marketable securities totaling $238.1 million, with restricted cash of $0.8 million[139]. Interest Income - Interest income, net for the three months ended September 30, 2023, was $3.0 million, an increase of $1.9 million compared to $1.1 million for the same period in 2022, driven by higher interest rates[105]. - Interest income, net rose to $8.0 million for the nine months ended September 30, 2023, an increase of $6.2 million compared to the same period in 2022, driven by higher interest rates[109]. Operating Activities - Cash used in operating activities was $43.6 million for the nine months ended September 30, 2023, down from $48.4 million in the same period of 2022[120]. - Total operating expenses for the nine months ended September 30, 2023, were $61.2 million, an increase of $5.4 million compared to $55.9 million for the same period in 2022[106]. Financing Activities - Financing activities generated $35.3 million in cash during the nine months ended September 30, 2023, mainly from the issuance of common stock under the ATM Program[125]. - The company has approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program as of September 30, 2023[113]. Market Risks - The company is exposed to market risks primarily related to interest rate risks in the ordinary course of business[138]. - The company is not currently exposed to significant market risk related to changes in foreign currency exchange rates, but future contracts with foreign vendors may introduce such risks[140]. Stock-Based Compensation - Stock-based compensation expense is recognized on a straight-line basis over the associated service period of the award[132]. - The company uses the Black-Scholes option pricing model to estimate the fair value of stock options on the date of grant[134]. - Expected volatility for stock options is derived from the average historical stock volatility over the expected term of the awards[135]. Other Information - The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future[94]. - The company plans to continue using third-party service providers for clinical development and manufacturing, as it does not currently have a sales force[92]. - The company engages vendors, CROs, and CMOs for preclinical development activities and clinical trials[133]. - Recent accounting pronouncements are detailed in Note 2 of the unaudited condensed financial statements for the nine months ended September 30, 2023[137].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM ! 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-3218129 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisdiction of incorporation or organization) 8 Clarke Drive, Suite 3 Cranbury, NJ 08512 (Ad ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regula ...

PART I. FINANCIAL INFORMATION [Condensed Financial Statements (Unaudited)](index=5&type=section&id=Item%201.%20Condensed%20Financial%20Statements%20(Unaudited)) The company reported an increased net loss of $18.4 million for Q1 2022, with total assets decreasing to $315.0 million due to reduced cash and cash equivalents, resulting in a net cash use of $18.0 million from operations [Condensed Balance Sheets (Unaudited)](index=5&type=section&id=Condensed%20Balance%20Sheets%20(Unaudited)) As of March 31, 2022, total assets decreased to $315.0 million, primarily due to reduced cash, while liabilities remained stable and stockholders' equity declined to $291.8 million due to the net loss for the period Condensed Balance Sheet Data (in thousands) | Account | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $115,772 | $172,467 | | Marketable securities, current | $167,221 | $124,696 | | Total current assets | $288,040 | $301,286 | | Total assets | $315,008 | $331,568 | | **Liabilities & Equity** | | | | Total current liabilities | $11,685 | $12,219 | | Total liabilities | $23,165 | $23,009 | | Accumulated deficit | $(186,159) | $(167,726) | | Total stockholders' equity | $291,843 | $308,559 | [Condensed Statements of Operations and Comprehensive Loss (Unaudited)](index=6&type=section&id=Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss%20(Unaudited)) For Q1 2022, the company reported an increased net loss of $18.4 million, or ($0.41) per share, primarily driven by higher operating expenses, including increased Research and Development and General and Administrative costs Condensed Statement of Operations (in thousands, except per share data) | Metric | Q1 2022 | Q1 2021 | | :--- | :--- | :--- | | Research and development | $11,836 | $7,500 | | General and administrative | $6,783 | $4,174 | | Total operating expenses | $18,619 | $11,674 | | Loss from operations | $(18,619) | $(11,674) | | Net loss | $(18,433) | $(11,602) | | Net loss per share | $(0.41) | $(0.26) | [Condensed Statements of Cash Flows (Unaudited)](index=8&type=section&id=Condensed%20Statements%20of%20Cash%20Flows%20(Unaudited)) Net cash used in operating activities increased to $18.0 million for the first quarter of 2022, with significant cash used in investing activities for marketable securities, resulting in a net decrease of $56.7 million in cash and cash equivalents during the quarter Condensed Statement of Cash Flows (in thousands) | Cash Flow Activity | Three Months Ended March 31, 2022 | Three Months Ended March 31, 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(17,998) | $(12,904) | | Net cash used in investing activities | $(38,825) | $(139,897) | | Net cash provided by financing activities | $128 | $162 | | **Net decrease in cash and cash equivalents** | **$(56,695)** | **$(152,639)** | [Notes to Unaudited Condensed Financial Statements](index=9&type=section&id=Notes%20to%20Unaudited%20Condensed%20Financial%20Statements) The notes confirm the company's precision oncology focus, state that current liquidity is sufficient for the next twelve months despite losses, and detail significant operating lease commitments and available shares under the equity incentive plan - The company is a precision oncology firm focused on developing small molecule therapies targeting p53, having devoted its efforts to R&D and raising capital since its 2013 inception[25](index=25&type=chunk) - As of March 31, 2022, the company had cash, cash equivalents, and marketable securities totaling **$294.8 million**. Management believes these funds are adequate to support operations for at least the next twelve months[27](index=27&type=chunk) - The company signed a lease for a new headquarters in Princeton, NJ, extending through 2032. As of March 31, 2022, total future minimum lease payments under all operating leases are **$16.7 million**[56](index=56&type=chunk)[58](index=58&type=chunk) - As of March 31, 2022, there were **5,321,975 shares** available for issuance under the 2020 Equity Incentive Plan[63](index=63&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's p53-targeting cancer therapies, anticipates continued significant operating expenses and net losses, and highlights strong liquidity of $294.8 million expected to fund operations through 2023 - The company is a precision oncology firm developing therapies targeting p53 mutations. Its lead product candidate, PC14586, is in a Phase 1/2 clinical trial, with the first patient dosed in Q4 2020[79](index=79&type=chunk)[80](index=80&type=chunk) - The company expects operating expenses to increase significantly as it advances product candidates through clinical development and seeks regulatory approval[80](index=80&type=chunk) - As of March 31, 2022, the company had **$294.8 million** in cash, cash equivalents, and marketable securities, which is expected to be sufficient to fund operations at least through 2023[96](index=96&type=chunk)[100](index=100&type=chunk) [Results of Operations](index=19&type=section&id=Results%20of%20Operations) Operating loss for Q1 2022 increased to $18.6 million, primarily driven by a $4.3 million rise in R&D expenses for the PC14586 clinical trial and a $2.6 million increase in G&A expenses due to expanded headcount and infrastructure Comparison of Operating Expenses (in thousands) | Expense Category | Q1 2022 | Q1 2021 | Change | | :--- | :--- | :--- | :--- | | Research and development | $11,836 | $7,500 | $4,336 | | General and administrative | $6,783 | $4,174 | $2,609 | | **Total operating expenses** | **$18,619** | **$11,674** | **$6,945** | - The **$4.3 million** increase in R&D expenses was primarily due to a **$3.7 million** increase in development costs for the PC14586 Phase 1/2 clinical trial and a **$0.7 million** increase in personnel-related costs[92](index=92&type=chunk) - The **$2.6 million** increase in G&A expenses was mainly due to a **$1.5 million** increase in personnel and office costs from higher headcount and a **$0.6 million** increase in facility costs for the new Princeton office[93](index=93&type=chunk)[97](index=97&type=chunk) [Liquidity and Capital Resources](index=20&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity, primarily from $294.8 million in cash and marketable securities from its 2020 IPO, is expected to fund operations through 2023, with future funding likely required for development and commercialization Financial Position Summary (in thousands) | Category | March 31, 2022 | December 31, 2021 | | :--- | :--- | :--- | | Cash and cash equivalents | $115,772 | $172,467 | | Total financial assets | $294,766 | $314,074 | | Total working capital | $276,355 | $289,067 | - The company's cash runway is expected to last at least through 2023, based on current research and development plans[100](index=100&type=chunk) - The company has a shelf registration statement on Form S-3 for a potential future offering of up to **$150.0 million**, though no shares have been sold under it as of the reporting date[96](index=96&type=chunk) [Critical Accounting Policies and Significant Judgments and Estimates](index=22&type=section&id=Critical%20Accounting%20Policies%20and%20Significant%20Judgments%20and%20Estimates) The company's critical accounting policies include Research and Development Costs, requiring estimates for accrued expenses, and Stock-Based Compensation, which uses the Black-Scholes model with significant assumptions for fair value determination - A key estimate is for accrued research and development expenses, which involves reviewing contracts and communicating with vendors (CROs, CMOs) to determine costs for services performed but not yet invoiced[116](index=116&type=chunk) - The fair value of stock options is estimated using the Black-Scholes model, which requires management to make significant assumptions, including using historical volatilities of comparable public companies due to its own limited trading history[117](index=117&type=chunk)[118](index=118&type=chunk)[119](index=119&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=24&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is from interest rates on its $294.8 million in short-term financial assets, which is not considered material, and it currently has no significant foreign currency exchange rate risk - The company's market risk is primarily from interest rate changes affecting its **$294.8 million** in cash, cash equivalents, and marketable securities, but this exposure is not considered material[122](index=122&type=chunk)[123](index=123&type=chunk) - There is no significant current exposure to foreign currency exchange rate risk, though this could become a factor with future international vendor contracts[124](index=124&type=chunk) [Controls and Procedures](index=24&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2022, with no material changes to internal control over financial reporting during the quarter - The Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective as of March 31, 2022[126](index=126&type=chunk) - No changes in internal control over financial reporting occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, these controls[127](index=127&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=25&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any legal proceedings that are expected to have a material adverse effect on its business - The company reports no current involvement in litigation or legal proceedings that would likely have a material adverse effect[130](index=130&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A.%20Risk%20Factors) No material changes to risk factors were reported, except for new disclosures concerning international operations, including differing regulatory requirements, sociopolitical instability, foreign currency fluctuations, and supply chain disruptions - No material changes to risk factors are reported, except for new disclosures regarding risks associated with international operations[131](index=131&type=chunk) - Newly highlighted international risks include: differing foreign regulatory requirements, sociopolitical instability, foreign currency fluctuations, and supply chain disruptions due to geopolitical conflicts or trade restrictions[134](index=134&type=chunk)[142](index=142&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=26&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities and no material change in the planned use of approximately $223.2 million in net proceeds from its September 2020 IPO - There were no unregistered sales of equity securities in the period[136](index=136&type=chunk) - The company received net proceeds of approximately **$223.2 million** from its IPO in September 2020, and there has been no material change in the planned use of these funds[137](index=137&type=chunk)[138](index=138&type=chunk) [Defaults Upon Senior Securities](index=26&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) None - The company reports no defaults upon senior securities[140](index=140&type=chunk) [Mine Safety Disclosures](index=26&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) Not applicable - This item is not applicable to the company[141](index=141&type=chunk) [Other Information](index=26&type=section&id=Item%205.%20Other%20Information) Not applicable - This item is not applicable to the company[142](index=142&type=chunk) [Exhibits](index=27&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including the company's certificate of incorporation, bylaws, various agreements, and certifications by the principal executive and financial officers